Johnson & Johnson
JNJ164.740USD
-2.520-1.51%
Cierre 07/31, 16:00（ET）Cotizaciones retrasadas 15 min
396.49BCap. mercado
18.18P/E TTM
Más Datos de Johnson & Johnson Compañía
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
Información de la empresa
Símbolo de cotizaciónJNJ
Nombre de la empresaJohnson & Johnson
Fecha de salida a bolsaSep 25, 1944
Fundada en1887
Director ejecutivoMr. Joaquin Boix Duato
Número de empleados138100
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 25
DirecciónOne Johnson & Johnson Plaza
CiudadNEW BRUNSWICK
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal08933
Teléfono17325242455
Sitio Webhttps://www.jnj.com/
Símbolo de cotizaciónJNJ
Fecha de salida a bolsaSep 25, 1944
Fundada en1887
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4047.85%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
10.90K
+30.72%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
-64.23%
Mrs. Anne M. Mulcahy
Mrs. Anne M. Mulcahy
Independent Director
Independent Director
8.41K
+3.87%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4047.85%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Oncology-DARZALEX
3.24B
14.79%
Interventional Solutions
2.10B
9.61%
Immunology-STELARA
1.63B
7.42%
Surgery-General
1.32B
6.04%
Surgery-Advanced
1.07B
4.90%
Other
12.53B
57.24%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
12.30B
56.21%
Europe
5.11B
23.34%
Asia-Pacific, Africa
3.31B
15.12%
Western Hemisphere, excluding U.S.
1.17B
5.33%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Oncology-DARZALEX
3.24B
14.79%
Interventional Solutions
2.10B
9.61%
Immunology-STELARA
1.63B
7.42%
Surgery-General
1.32B
6.04%
Surgery-Advanced
1.07B
4.90%
Other
12.53B
57.24%
Estadísticas de accionistas
Actualizado: mar., 13 de may
Actualizado: mar., 13 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.67%
State Street Global Advisors (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.36%
Geode Capital Management, L.L.C.
2.47%
JP Morgan Asset Management
1.46%
Other
75.48%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.67%
State Street Global Advisors (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.36%
Geode Capital Management, L.L.C.
2.47%
JP Morgan Asset Management
1.46%
Other
75.48%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
38.92%
Investment Advisor/Hedge Fund
23.82%
Research Firm
3.09%
Pension Fund
2.21%
Bank and Trust
2.18%
Insurance Company
1.64%
Sovereign Wealth Fund
1.36%
Hedge Fund
0.57%
Foundation
0.10%
Other
26.09%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
5912
1.78B
73.98%
-417.03K
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
232.98M
9.68%
+1.17M
+0.50%
Mar 31, 2025
State Street Global Advisors (US)
133.79M
5.56%
-666.37K
-0.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
129.14M
5.37%
-857.93K
-0.66%
Mar 31, 2025
Geode Capital Management, L.L.C.
59.38M
2.47%
+1.72M
+2.98%
Mar 31, 2025
JP Morgan Asset Management
35.25M
1.47%
+11.21M
+46.62%
Mar 31, 2025
State Farm Insurance Companies
34.37M
1.43%
--
--
Mar 31, 2025
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
24.07M
1%
+1.16M
+5.06%
Mar 31, 2025
Wellington Management Company, LLP
22.65M
0.94%
-1.71M
-7.02%
Mar 31, 2025
BlackRock Asset Management Ireland Limited
19.70M
0.82%
-178.45K
-0.90%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
iShares U.S. Pharmaceuticals ETF
22.5%
FT Vest DJIA Dogs 10 Target Income ETF
9.95%
Franklin Income Focus ETF
7.87%
First Trust NASDAQ Pharmaceuticals ETF
7.61%
Health Care Select Sector SPDR Fund
7.48%
iShares U.S. Healthcare ETF
7.17%
Proshares Ultra Health Care
7.06%
Fidelity MSCI Health Care Index ETF
6.72%
Touchstone Strategic Income ETF
6.64%
JPMorgan Healthcare Leaders ETF
6.58%
Ver más
iShares U.S. Pharmaceuticals ETF
Proporción22.5%
FT Vest DJIA Dogs 10 Target Income ETF
Proporción9.95%
Franklin Income Focus ETF
Proporción7.87%
First Trust NASDAQ Pharmaceuticals ETF
Proporción7.61%
Health Care Select Sector SPDR Fund
Proporción7.48%
iShares U.S. Healthcare ETF
Proporción7.17%
Proshares Ultra Health Care
Proporción7.06%
Fidelity MSCI Health Care Index ETF
Proporción6.72%
Touchstone Strategic Income ETF
Proporción6.64%
JPMorgan Healthcare Leaders ETF
Proporción6.58%
Dividendos
Un total de
56.79B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
